Literature DB >> 10852554

Diagnostic criteria for primary progressive multiple sclerosis: a position paper.

A J Thompson1, X Montalban, F Barkhof, B Brochet, M Filippi, D H Miller, C H Polman, V L Stevenson, W I McDonald.   

Abstract

The unique clinical characteristics of primary progressive multiple sclerosis (PPMS) pose particular diagnostic difficulties, both in excluding other causes of progressive syndromes and in confirming the diagnosis of MS, which is not adequately addressed by current diagnostic criteria. This article presents new diagnostic criteria developed by a group of investigators on the basis of a review of their considerable experience with PPMS. (We conclude that at least 1 year of clinical progression must be documented before a diagnosis of PPMS is made.) Three levels of diagnostic certainty have been defined-definite, probable, and possible--based on clinical findings, abnormal cerebrospinal fluid, abnormalities on magnetic resonance imaging (MRI) of the brain and spinal cord, and evoked potentials. In definite PPMS, evidence of intrathecal synthesis of immunoglobulin G together with one of the following three MRI criteria is required: (1) nine brain lesions, (2) two spinal cord lesions, or (3) four to eight brain lesions and one spinal cord lesion. Preliminary testing of these criteria was carried out on a cohort of 156 patients participating in a European natural history study of PPMS: 64% fulfilled the criteria for definite PPMS, 35% for probable PPMS, and only 1% for possible PPMS. These criteria now require prospective validation in a cohort of newly diagnosed patients and by postmortem examination.

Entities:  

Mesh:

Year:  2000        PMID: 10852554

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  73 in total

1.  HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis.

Authors:  A E Hensiek; S J Sawcer; R Feakes; J Deans; A Mander; E Akesson; R Roxburgh; F Coraddu; S Smith; D A S Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 2.  Management of secondary-progressive multiple sclerosis.

Authors:  Gavin Giovannoni
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 3.  [Differential diagnosis of chronic inflammatory diseases of the central nervous system. Cerebrospinal fluid diagnosis and immunological parameters].

Authors:  D Reske; H-F Petereit
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

Review 4.  Interferon-β-1b: a review of its use in multiple sclerosis.

Authors:  Greg L Plosker
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

5.  White and gray matter damage in primary progressive MS: The chicken or the egg?

Authors:  Benedetta Bodini; Declan Chard; Daniel R Altmann; Daniel Tozer; David H Miller; Alan J Thompson; Claudia Wheeler-Kingshott; Olga Ciccarelli
Journal:  Neurology       Date:  2015-12-16       Impact factor: 9.910

6.  A multiparametric evaluation of regional brain damage in patients with primary progressive multiple sclerosis.

Authors:  Antonia Ceccarelli; Maria A Rocca; Paola Valsasina; Mariaemma Rodegher; Elisabetta Pagani; Andrea Falini; Giancarlo Comi; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

7.  Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France.

Authors:  M Debouverie; S Louis; S Pittion-Vouyovitch; T Roederer; H Vespignani
Journal:  J Neurol       Date:  2007-06-25       Impact factor: 4.849

8.  A cytoskeleton motor protein genetic variant may exert a protective effect on the occurrence of multiple sclerosis: the janus face of the kinesin light-chain 1 56836CC genetic variant.

Authors:  Zoltan Szolnoki; Andras Kondacs; Yvette Mandi; Ferenc Somogyvari
Journal:  Neuromolecular Med       Date:  2007-10-13       Impact factor: 3.843

Review 9.  [Dementia as a primary symptom in late onset multiple sclerosis. Case series and review of the literature].

Authors:  T Leyhe; C Laske; G Buchkremer; H Wormstall; H Wiendl
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

10.  Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis.

Authors:  D R Booth; A T Arthur; S M Teutsch; C Bye; J Rubio; P J Armati; J D Pollard; R N S Heard; G J Stewart
Journal:  J Mol Med (Berl)       Date:  2005-08-02       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.